The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Tumor cell lysates as immunogenic sources for cancer vaccine design
Open accessAbstract
Autologous dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) are a promising immunological tool for cancer therapy. These stimulate the antitumor response and immunological memory generation. Nevertheless, many patients remain refractory to DC approaches. Antigen (Ag) delivery to DCs is relevant to vaccine success, and antigen peptides, tumor-associated proteins, tumor cells, autologous tumor lysates, and tumor-derived mRNA have been tested as Ag sources. Recently, DCs loaded with allogeneic tumor cell lysates were used to induce a potent immunological response. This strategy provides a reproducible pool of almost all potential Ags suitable for patient use, independent of MHC haplotypes or autologous tumor tissue availability. However, optimizing autologous tumor cell lysate preparation is crucial to enhancing efficacy. This review considers the role of cancer cell-derived lysates as a relevant source of antigens and as an activating factor for ex vivo therapeutic DCs capable of responding to neoplastic cells. These promising therapies are associated with the prolonged survival of advanced cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 2×
“To date, one of the most successful immunotherapeutic approaches has been sipuleucel-T (Provenge , Dendreon), which is the first FDAapproved cell-based therapy for the treatment of hormone-refractory prostate cancer patients.(51) Sipuleucel-T consists of autologous PBMCs, including DCs, B cells, monocytes, and natural…”
BackgroundMethodSallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 2×
“In fact, Gamma and UVC-irradiation are able to trigger CRT exposure, an “eat me” signal for APCs, on apoptotic cancer cells.(92,107) Recently, the use of hypochlorous acid before lysate purification was examined as a way to improve the immunogenicity of ovarian cancer lysates through oxidation.”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Roles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation
Krysko, D. V., Agostinis, P., Krysko, O., Garg, A. D., Bachert, C., Lambrecht, B. N., & Vandenabeele, P. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.005 · Cited by 680
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Decoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 4×
“In this context, specific DAMPs such as surface exposed CRT, secreted ATP, and passively released HMGB1 and subsequent interactions with phagocytosis receptors, purinergic receptors, and PRRs, respectively, are required for ICD, and this ultimately leads to the activation of potent anticancer immunity (Table 3).(85,96…”
BackgroundInfluentialObeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474 · cited 1×
“In fact, Gamma and UVC-irradiation are able to trigger CRT exposure, an “eat me” signal for APCs, on apoptotic cancer cells.(92,107) Recently, the use of hypochlorous acid before lysate purification was examined as a way to improve the immunogenicity of ovarian cancer lysates through oxidation.”
BackgroundTherapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · cited 2×
“During the last 2 decades, several immunotherapy approaches have been tested as alternative treatments against solid and hematological malignancies.(1) The use of recombinant cytokines such as IL-2 and IFN-a, T cell-mediated adoptive therapies, monoclonal antibodies, and dendritic cells (DCs)-based vaccines, among oth…”
Background
Cited by
Phuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
CD8+ T cell exhaustion and cancer immunotherapy
Wang, Q., Qin, Y., & Li, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216043 · Cited by 155
Koeneman, B. J., Schreibelt, G., Gorris, M. A. J., Hins - de Bree, S., Westdorp, H., Ottevanger, P. B., & de Vries, I. J. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368103 · Cited by 24
“None of these sources has yet proven to be superior to the other as both have their advantages and disadvantages (20).”
BackgroundYe, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“82 Ex vivo antigen loading entails the isolation of patient-derived APCs, most commonly monocyte-derived dendritic cells, which are subsequently pulsed in vitro with tumor-derived materials such as irradiated whole cells, lysates, or puri fi ed membrane fractions.”
Metadata
- Authors
- González, F. E., Gleisner, A., Falcón-Beas, F., Osorio, F., López, M. N., & Salazar-Onfray, F.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-11-02
- Volume
- 10
- Issue
- 11
- Pages
- 3261-3269
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W2163838780
- Cited by
- 160
- References
- 13
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.